Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells

Journal of Endocrinological Investigation

Volumn 30, Issue 9, 2007, Pages

  Benvenuti, S ^a   Cellai, I ^a   Luciani, P ^a   Deledda, C ^a   Baglioni, S ^a   Giuliani, C ^a   Saccardi, R ^a   Mazzanti, B ^a   Dal Pozzo, S ^a   Mannucci, E ^a   Peri, A ^a   Serio, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adipocytes; Mesenchymal stem cells; Osteoblasts; Osteopenia; Rosiglitazone

Indexed keywords

FAT DROPLET; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 4; GLITAZONE DERIVATIVE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINEAGE; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFORMATION; MESENCHYMAL STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PROTEIN EXPRESSION;

EID: 36949018942     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350807     Document Type: Article

References (14)

1. Hannele YJ. Thiazolidinediones. N Engl J Med 2004, 351: 1106-18.
2. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in order diabetic adults. J Clin Endocrinol Metab 2006, 91: 3349-54.
3. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferators-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92: 1305-10.
4. Kahn SE, Haffner SM, Heise MA, et al, ADOPT Study Group. Glycemic clurability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355: 2427-43.
5. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferators-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143: 2376-84.
6. Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteblast/ osteocyte apoptosis. J Endocrinol 2004, 183: 203-16.
7. Benvenuti S, Saccardi R, Luciani P, et al. Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-I. Exp Cell Res 2006, 312: 2592-604.
8. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284: 143-7.
9. Luciani P, Ferruzzi P, Arnaldi G, et al. Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-I in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 2004, 89: 1332-9.
10. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8: 315-7.
11. Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113: 846-55.
12. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3: 379-89.
13. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145: 401-6.
14. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003, 144: 5081-8.